Overview
Reunion Neuroscience is developing RE104, a novel psychedelic compound with a shorter duration of action than psilocybin, targeting postpartum depression and major depressive disorder. Their approach aims to improve practicality of psychedelic-assisted therapy.
More in Mental Health Tech
Latest industry news
Flourish Emerges from Stealth with Bezos and Google Ventures Backing to Target Brain Health
2026-07-11 · Funding
BrainCo Pushes to Commercialize Brain-Tech as China's BCI Ambitions Come Into Focus
2026-07-10 · Industry
FDA Clears PoNS Device for Stroke Rehabilitation, Broadening Neurostimulation's Clinical Reach
2026-07-09 · Policy
Neurovalens Wins FDA Approval for PTSD Therapy Targeting US Veterans
2026-07-08 · Policy
Company details
Category
💙 Mental Health Tech
Location
Montreal, Canada
Funding
Public · NASDAQ: REUN
Website
reunionneuroscience.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →